Drug Profile
Research programme: pulmonary arterial hypertension therapies - Apollo Therapeutics
Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Apollo Therapeutics
- Developer Apollo Therapeutics; Imperial College of Science, Technology and Medicine
- Class Antihypertensives
- Mechanism of Action Carrier protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pulmonary arterial hypertension
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for research development in Pulmonary-arterial-hypertension in United Kingdom
- 22 Feb 2017 Early research in Pulmonary arterial hypertension in United Kingdom (unspecified route)